Cargando…
Glutamate dehydrogenase as a biomarker for mitotoxicity; insights from furosemide hepatotoxicity in the mouse
Glutamate dehydrogenase (GLDH) is a liver-specific biomarker of hepatocellular damage currently undergoing qualification as a drug development tool. Since GLDH is located within the mitochondrial matrix, it has been hypothesized that it might also be useful in assessing mitotoxicity as an initiating...
Autores principales: | Church, Rachel J., Schomaker, Shelli J., Eaddy, J. Scott, Boucher, Germaine G., Kreeger, John M., Aubrecht, Jiri, Watkins, Paul B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546462/ https://www.ncbi.nlm.nih.gov/pubmed/33035276 http://dx.doi.org/10.1371/journal.pone.0240562 |
Ejemplares similares
-
Biomarkers of mitotoxicity after acute liver injury: Further insights into the interpretation of glutamate dehydrogenase
por: McGill, Mitchell R., et al.
Publicado: (2021) -
Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury
por: Aubrecht, Jiri, et al.
Publicado: (2013) -
Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments
por: Schomaker, Shelli, et al.
Publicado: (2020) -
Editorial: Lipotoxicity, mitotoxicity, and drug targets
por: Krako Jakovljevic, Nina, et al.
Publicado: (2023) -
Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human
por: Krauskopf, Julian, et al.
Publicado: (2017)